Fighting against age discrimination in clinical trials

Antonio Cherubini, Susanna Del Signore, Joe Ouslander, Todd Semla, Jean Pierre Michel

Research output: Contribution to journalArticlepeer-review


At the American Geriatrics Society 2008 Annual Meeting, representatives of two geriatric societies, the European Union Geriatric Medicine Societies and the American Geriatrics Society, and two regulatory agencies, the U.S. Food and Drug Administration and the European Medicine Agency, conducted a roundtable discussion aimed at reviewing the participation of older people in clinical trials. This article summarizes the important issues discussed at the meeting. Historically, regulatory agencies started to promote the inclusion of older participants in clinical trials in the late 1980s. The identification of the causes of delay in including older participants in clinical trials, as well as of the ongoing bias against including older participants with multiple comorbidities, is important to help geriatricians fight against age discrimination in clinical trials. To overcome this problem, geriatrics societies and regulatory agencies must work together to propose new definitions, study designs, and technologies aimed at improving the evaluation of drugs in older people with multiple comorbidities and polypharmacy.

Original languageEnglish
Pages (from-to)1791-1796
Number of pages6
JournalJournal of the American Geriatrics Society
Issue number9
Publication statusPublished - 2010


  • clinical trial
  • exclusion
  • geriatric medicine
  • older participant
  • regulatory agency

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)


Dive into the research topics of 'Fighting against age discrimination in clinical trials'. Together they form a unique fingerprint.

Cite this